Intrexon Corp (XON) Short Interest Up 6.2% in January

Intrexon Corp (NYSE:XON) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 33,348,255 shares, a growth of 6.2% from the January 15th total of 31,400,806 shares. Currently, 70.3% of the shares of the company are short sold. Based on an average daily volume of 1,724,726 shares, the days-to-cover ratio is currently 19.3 days.

Shares of Intrexon stock traded up $0.09 on Monday, hitting $7.50. 690,964 shares of the company’s stock were exchanged, compared to its average volume of 1,479,752. Intrexon has a 1 year low of $6.21 and a 1 year high of $20.16.

Intrexon (NYSE:XON) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.21). The firm had revenue of $32.45 million for the quarter, compared to analyst estimates of $35.98 million. Intrexon’s revenue was down 29.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.33) EPS.



In related news, insider Thomas D. Reed sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 31st. The shares were sold at an average price of $6.36, for a total value of $190,800.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Nir Nimrodi sold 4,058 shares of the firm’s stock in a transaction that occurred on Thursday, January 3rd. The stock was sold at an average price of $7.07, for a total transaction of $28,690.06. Following the completion of the sale, the insider now owns 9,766 shares in the company, valued at approximately $69,045.62. The disclosure for this sale can be found here. Insiders sold 71,297 shares of company stock worth $461,321 in the last 90 days. 48.20% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Intrexon by 4.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,823 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 1,835 shares during the last quarter. Raymond James & Associates lifted its holdings in Intrexon by 11.0% during the fourth quarter. Raymond James & Associates now owns 28,634 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,834 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Intrexon by 1.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 161,385 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 2,882 shares in the last quarter. Quantamental Technologies LLC purchased a new position in Intrexon during the fourth quarter valued at $28,000. Finally, Voya Investment Management LLC lifted its holdings in Intrexon by 21.0% during the second quarter. Voya Investment Management LLC now owns 26,130 shares of the biotechnology company’s stock valued at $364,000 after purchasing an additional 4,531 shares in the last quarter. Institutional investors and hedge funds own 84.92% of the company’s stock.

Separately, Zacks Investment Research upgraded shares of Intrexon from a “hold” rating to a “strong-buy” rating and set a $8.75 price target on the stock in a research note on Saturday, January 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Intrexon has a consensus rating of “Hold” and a consensus price target of $28.50.

WARNING: This story was published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/02/11/intrexon-corp-xon-short-interest-up-6-2-in-january.html.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Read More: Buyback

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply